CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease | BMC Gastroenterology
Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup. Clin Liver Dis (Hoboken). 2012;1(4):99–103.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
Williams VF, Taubman SB, Stahlman S. Non-alcoholic fatty liver disease (NAFLD), active component, U.S. Armed Forces, 2000–2017. Msmr. 2019;26(1):2–11.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54.
Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16(4):391–7.
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.
Petrick JL, Thistle JE, Zeleniuch-Jacquotte A, Zhang X, Wactawski-Wende J, Van Dyke AL, Stampfer MJ, Sinha R, Sesso HD, Schairer C. Body mass index, diabetes and intrahepatic cholangiocarcinoma risk: the liver cancer pooling project and meta-analysis. Am J Gastroenterol. 2018;113(10):1494.
Onyekwere CA, Ogbera AO, Samaila AA, Balogun BO, Abdulkareem FB. Nonalcoholic fatty liver disease: Synopsis of current developments. Niger J Clin Pract. 2015;18(6):703–12.
Jung ES, Lee K, Yu E, Kang YK, Cho MY, Kim JM, Moon WS, Jeong JS, Park CK, Park JB, et al. Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease. J Pathol Transl Med. 2016;50(3):190–6.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.
Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(2):475–85.
Ahn JS, Sinn DH, Gwak GY, Kim JM, Kwon CH, Joh JW, Paik YH, Choi MS, Lee JH, Koh KC, et al. Steatosis among living liver donors without evidence of fatty liver on ultrasonography: potential implications for preoperative liver biopsy. Transplantation. 2013;95(11):1404–9.
Tanaka N, Tanaka E, Sheena Y, Komatsu M, Okiyama W, Misawa N, Muto H, Umemura T, Ichijo T, Matsumoto A, et al. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 2006;26(8):956–63.
Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007;189(6):W320-323.
Qayyum A, Chen DM, Breiman RS, Westphalen AC, Yeh BM, Jones KD, Lu Y, Coakley FV, Callen PW. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? Clin Imaging. 2009;33(2):110–5.
Esterson YB, Grimaldi GM. Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018;22(1):93–108.
Chartampilas E. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones (Athens). 2018;17(1):69–81.
Byun J, Lee SS, Sung YS, Shin Y, Yun J, Kim HS. Yu Es, Lee S-G, Lee M-g: CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: development and validation of diagnostic cut-off values in a large cohort with pathological reference standard. Eur Radiol. 2018;29(8):4427–35.
Iwasaki M, Takada Y, Hayashi M, Minamiguchi S, Haga H, Maetani Y, Fujii K, Kiuchi T, Tanaka K. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation. 2004;78(10):1501–5.
European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.
Polanco-Briceno S, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res Notes. 2016;9:157.
Kallman JB, Arsalla A, Park V, Dhungel S, Bhatia P, Haddad D, Wheeler A, Younossi ZM. Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Aliment Pharmacol Ther. 2009;29(9):1019–24.
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):1–7.
Kang SH, Lee HW, Yoo J-J, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H. KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27(3):363.
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-397. e310.
Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73.
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65.
Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H. Wong VW-S, Peleg N: Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611-1625. e1612.
Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA, Network NSCR. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials. Hepatology. 2019;70(2):522–31.
Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, Cha BS, Lee HC, Balkau B, Lee WY, et al. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS ONE. 2014;9(9):e107584.
Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8.
Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, et al. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel). 2021;11(1):132.
Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7392–402.
Lee DH. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol. 2017;23(4):290–301.
Kramer H, Pickhardt PJ, Kliewer MA, Hernando D, Chen GH, Zagzebski JA, Reeder SB. Accuracy of Liver Fat Quantification With Advanced CT, MRI, and Ultrasound Techniques: Prospective Comparison With MR Spectroscopy. AJR Am J Roentgenol. 2017;208(1):92–100.
Guo Z, Blake GM, Li K, Liang W, Zhang W, Zhang Y, Xu L, Wang L, Brown JK, Cheng X, et al. Liver Fat Content Measurement with Quantitative CT Validated against MRI Proton Density Fat Fraction: A Prospective Study of 400 Healthy Volunteers. Radiology. 2020;294(1):89–97.
Li X, Xia M, Ma H, Hu Y, Yan H, He W, Lin H, Zhao N, Gao J, Gao X. Liver fat content, evaluated through semi-quantitative ultrasound measurement, is associated with impaired glucose profiles: a community-based study in Chinese. PLoS ONE. 2013;8(7):e65210.
Ducluzeau PH, Boursier J, Bertrais S, Dubois S, Gauthier A, Rohmer V, Gagnadoux F, Leftheriotis G, Cales P, Andriantsitohaina R, et al. MRI measurement of liver fat content predicts the metabolic syndrome. Diabetes Metab. 2013;39(4):314–21.
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.
Chan W-K, Treeprasertsuk S, Goh GB-B, Fan J-G, Song MJ, Charatcharoenwitthaya P, Duseja A, Dan Y-Y, Imajo K, Nakajima A. Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2019;17(12):2570–25802537.